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Introduction
Neutrophils are the first line of defence against bacterial 
infection, and formation of neutrophil extracellular traps 
(NETs) is an important protective mechanism. NETs can 
also be harmful by inducing intravascular coagulation and 
multi-organ failure (MOF) in animal models.1–6 Although 
increasingly considered as important therapeutic targets,7–9 
there is currently no robust and specific measure of NET 
formation to inform clinical care and enable precision medicine 
in patients on the intensive care unit (ICU). The aim of this 
study is to establish a novel assay for measuring NETs and 
assess its clinical significance.
Materials and methods
A prospective cohort of 341 consecutive adult ICU patients was 
recruited at the Royal Liverpool University Hospital, following 
written informed consent. The NET-forming capacity of ICU 
admission blood samples was semi-quantified by directly 
incubating patient plasma with isolated healthy neutrophils 
ex vivo. Associations of NET-forming capacity with sequential 
organ failure assessment (SOFA) scores, disseminated 
intravascular coagulation (DIC) and 28-day mortality were 
analysed and compared with available NET assays. Cytokine 
analysis and inhibitor studies were performed to determine the 
driving factors of NET formation in patients. To determine the 
pathological relevance of NETs, complementary in vivo studies 
were performed in mouse models of sepsis (caecal ligation and 
puncture (CLP) or intraperitoneal injection of Escherichia coli), 
without or with anti-NET therapy.
Results and discussion
We observed that NETs were directly induced by heterologous 
healthy neutrophils incubated with plasma taken from ICU 
patients on ICU admission, but not from healthy donors 
(unless incubated with 100 nM PMA). Using this novel assay 
we could stratify patients into four groups: those with absent 
(22.0%), mild (49.9%), moderate (14.4%) and strong (13.8%) 
NET formation. Strong NET formation was predominantly 
found in sepsis (p<0.0001) and was associated with higher 
SOFA scores. Adjusted by APACHE II, multivariate regression 
showed that measuring the degree of NET formation on ICU 
admission could independently predict DIC and mortality, 
whereas other NET assays, eg cell-free DNA, myeloperoxidase 
and myeloperoxidase–DNA complexes, could not. Interleukin 
(IL)-8 levels were found to be strongly associated with NET 
formation, and inhibiting IL-8 significantly attenuated 
NETosis.
Using mouse models of sepsis, we could monitor NET 
formation using plasma, which was associated with NET-
positive staining (cit-H3) in the lung tissue. This was 
associated with increased fibrin deposition within the lung 
tissue, along with lung injury scores and circulating markers 
of liver (blood urea nitrogen; CLP: p=0.005,  
E coli : p<0.001), kidney (alanine aminotransferase; CLP: 
p=0.01, E coli : p=0.002) and cardiac injury (cardiac 
troponin I; CLP: p<0.001, E coli : p<0.001). By targeting IL-8 
(using a clinically relevant compound, reparixin) in septic 
mice, we were able to significantly inhibit NET formation, 
fibrin deposition and organ injury, and improve survival 
times (p=0.004).
Conclusion
Our new NET assay directly measures the NET-forming 
capacity in patient plasma. This could guide clinical 
management and enable identification of NET-inducing factors 
in individual patients for targeted treatment and personalised 
ICU medicine. We identify IL-8 as a major driving factor 
in sepsis, with anti-IL-8 therapy in septic mice significantly 
reducing NET-induced organ damage and mortality. n
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